3rd Quarter - Report

ALLIANCE FOR REGENERATIVE MEDICINE for ALLIANCE FOR REGENERATIVE MEDICINE

Firm
Client
Income
—
Expenses
$120,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products FDA appropriations and staffing, specifically at CBER and OTP FDA oversight, including adaptive regulatory pathways for cell and gene therapies Value-based payment legislation and related CMS regulations Biologics regulation Prescription Drug User Fee Act (PDUFA) Medicaid Medicare NIH appropriations HHS oversight HHS staffing and OPM issues Federal support of medical research Pharmaceutical tariffs Biotechnology manufacturing

LobbyistCovered position, as disclosed
JOHN AGUILAR —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Commerce, Dept of (DOC); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.